Avidity Biosciences, a Torrey Pines biopharmaceutical company, has closed its underwritten public offering of 12.13 million shares of common stock. That includes 1.58 million shares sold pursuant to ...
The biotech received some positive news from a top regulator. That organization released a partial clinical hold on a key investigational drug. On Thursday, Avidity announced that the U.S. Food and ...
We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against other ...
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor Therapeutics, CureDuchenne CSO Michael Kelly sees “momentum” in the Duchenne ...
WATERFORD, Wis., Oct. 26, 2020 /CNW/ -- Today, Avidity Science announces significant steps in expanding its global leadership in biomedical research solutions via the acquisition of Bio Medic Data ...
LA JOLLA, Calif., Jan. 11, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody ...
An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...
Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company ...
Avidity Biosciences, Inc. (NASDAQ:RNA) revealed topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE program in Facioscapulohumeral Muscular ...
FSHD Society to host Avidity webinar on positive initial data from the Phase 1/2 FORTITUDE™ trial for people living with FSHD today at 1:00 p.m. ET "This World FSHD Day, we are excited to be joining ...
Avidity Biosciences Inc. said Tuesday it’s expanding its cardiovascular collaboration with Bristol Myers Squibb Co. in a deal that will see Avidity receive $100 million upfront with the potential to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results